{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T19:05:46Z","timestamp":1792868746786,"version":"4.5.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T00:00:00Z","timestamp":1715904000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Despite the growing use of immune checkpoint inhibitors (ICI) in cancer treatment, data regarding ICI-associated pericardial disease are primarily derived from case reports and case series. ICI related pericardial disease can be difficult to diagnose and is associated with significant morbidity. We conducted a systematic review to further characterize the epidemiology, clinical presentation, and outcomes of this patient population.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A search of four databases resulted in 31 studies meeting inclusion criteria. Patients\u2009&gt;\u200918 years old who presented with ICI mediated pericardial disease were included. Intervention was medical\u2009+\u2009surgical therapy and outcomes were development of cardiac tamponade, morbidity, and mortality.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Thirty- eight patients across 31 cases were included. Patients were majority male (72%) with a median age of 63. Common symptoms included dyspnea (59%) and chest pain (32%), with 41% presenting with cardiac tamponade. Lung cancer (81%) was the most prevalent, and nivolumab (61%) and pembrolizumab (34%) were the most used ICIs. Pericardiocentesis was performed in 68% of patients, and 92% experienced symptom improvement upon ICI cessation. Overall mortality was 16%.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This study provides the most comprehensive analysis of ICI-mediated pericardial disease to date. Patients affected were most commonly male with lung cancer treated with either Nivolumab or Pembrolizumab. Diagnosis may be challenging in the setting of occult presentation with normal EKG and physical exam as well as delayed onset from therapy initiation. ICI-associated pericardial disease demonstrates high morbidity and mortality, as evidenced by a majority of patients requiring pericardiocentesis.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40959-024-00234-0","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:02:05Z","timestamp":1715925725000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Immune checkpoint inhibitors and pericardial disease: a systematic review"],"prefix":"10.1186","volume":"10","author":[{"given":"Sarah E.","family":"Mudra","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny L.","family":"Rayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashwin K.","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason Z.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meredith","family":"Njus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McGowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazi A.","family":"Kalam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charalompos","family":"Charalampous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Schleicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad","family":"Majid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alvena","family":"Syed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Yesilyaprak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan L.","family":"Klein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,5,17]]},"reference":[{"issue":"12","key":"234_CR1","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","volume":"19","author":"JE Salem","year":"2018","unstructured":"Salem JE, Manouchehri A, Moey M, et al. Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study. Lancet Oncol. 2018;19(12):1579\u201389. https:\/\/doi.org\/10.1016\/S1470-2045(18)30608-9","journal-title":"Lancet Oncol"},{"issue":"2","key":"234_CR2","doi-asserted-by":"publisher","first-page":"e013757","DOI":"10.1161\/JAHA.119.013757","volume":"9","author":"N Palaskas","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020;9(2):e013757. https:\/\/doi.org\/10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"issue":"8","key":"234_CR3","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1634\/theoncologist.2018-0130","volume":"23","author":"S Ganatra","year":"2018","unstructured":"Ganatra S, Neilan TG. Immune Checkpoint inhibitor-Associated Myocarditis. Oncologist. 2018;23(8):879\u201386. https:\/\/doi.org\/10.1634\/theoncologist.2018-0130","journal-title":"Oncologist"},{"key":"234_CR4","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372:n71. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"issue":"7","key":"234_CR5","doi-asserted-by":"publisher","first-page":"3178","DOI":"10.1007\/s12325-020-01386-y","volume":"37","author":"ML Canale","year":"2020","unstructured":"Canale ML, Camerini A, Casolo G, et al. Incidence of Pericardial Effusion in patients with Advanced Non-small Cell Lung Cancer receiving immunotherapy. Adv Ther. 2020;37(7):3178\u201384. https:\/\/doi.org\/10.1007\/s12325-020-01386-y","journal-title":"Adv Ther"},{"issue":"11","key":"234_CR6","doi-asserted-by":"publisher","first-page":"584","DOI":"10.4330\/wjc.v12.i11.584","volume":"12","author":"N Nso","year":"2020","unstructured":"Nso N, Antwi-Amoabeng D, Beutler BD, et al. Cardiac adverse events of immune checkpoint inhibitors in oncology patients: a systematic review and meta-analysis. World J Cardiol. 2020;12(11):584\u201398. https:\/\/doi.org\/10.4330\/wjc.v12.i11.584","journal-title":"World J Cardiol"},{"issue":"1","key":"234_CR7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40959-022-00130-5","volume":"8","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S. Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardio-Oncol Lond Engl. 2022;8(1):3. https:\/\/doi.org\/10.1186\/s40959-022-00130-5","journal-title":"Cardio-Oncol Lond Engl"},{"issue":"8","key":"234_CR8","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.amjcard.2019.01.013","volume":"123","author":"N Palaskas","year":"2019","unstructured":"Palaskas N, Morgan J, Daigle T, et al. Targeted Cancer Therapies with Pericardial effusions requiring Pericardiocentesis focusing on Immune Checkpoint inhibitors. Am J Cardiol. 2019;123(8):1351\u20137. https:\/\/doi.org\/10.1016\/j.amjcard.2019.01.013","journal-title":"Am J Cardiol"},{"issue":"12","key":"234_CR9","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S1470-2045(18)30622-3","volume":"19","author":"G Varricchi","year":"2018","unstructured":"Varricchi G, Galdiero MR, Mercurio V, Bonaduce D, Marone G, Tocchetti CG. Pharmacovigilating cardiotoxicity of immune checkpoint inhibitors. Lancet Oncol. 2018;19(12):1545\u20136. https:\/\/doi.org\/10.1016\/S1470-2045(18)30622-3","journal-title":"Lancet Oncol"},{"issue":"2","key":"234_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.jaccas.2019.11.080","volume":"2","author":"J Chahine","year":"2020","unstructured":"Chahine J, Collier P, Maroo A, Tang WHW, Klein AL. Myocardial and pericardial toxicity Associated with Immune checkpoint inhibitors in Cancer patients. JACC Case Rep. 2020;2(2):191\u20139. https:\/\/doi.org\/10.1016\/j.jaccas.2019.11.080","journal-title":"JACC Case Rep"},{"issue":"6","key":"234_CR11","doi-asserted-by":"publisher","first-page":"e002771","DOI":"10.1136\/jitc-2021-002771","volume":"9","author":"J Gong","year":"2021","unstructured":"Gong J, Drobni ZD, Zafar A, et al. Pericardial disease in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9(6):e002771. https:\/\/doi.org\/10.1136\/jitc-2021-002771","journal-title":"J Immunother Cancer"},{"issue":"22","key":"234_CR12","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.2169\/internalmedicine.7219-21","volume":"60","author":"R Sawada","year":"2021","unstructured":"Sawada R, Matsui Y, Uchino J, et al. Late-onset Pleural and Pericardial Effusion as Immune-related adverse events after 94 cycles of Nivolumab. Intern Med Tokyo Jpn. 2021;60(22):3585\u20138. https:\/\/doi.org\/10.2169\/internalmedicine.7219-21","journal-title":"Intern Med Tokyo Jpn"},{"issue":"7","key":"234_CR13","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1007\/s11912-023-01414-4","volume":"25","author":"LI Yousif","year":"2023","unstructured":"Yousif LI, Screever EM, Versluis D, et al. Risk factors for Immune Checkpoint inhibitor-mediated Cardiovascular Toxicities. Curr Oncol Rep. 2023;25(7):753\u201363. https:\/\/doi.org\/10.1007\/s11912-023-01414-4","journal-title":"Curr Oncol Rep"},{"issue":"18","key":"234_CR14","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1056\/NEJMoa1609214","volume":"375","author":"DB Johnson","year":"2016","unstructured":"Johnson DB, Balko JM, Compton ML, et al. Fulminant myocarditis with combination Immune Checkpoint Blockade. N Engl J Med. 2016;375(18):1749\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1609214","journal-title":"N Engl J Med"},{"key":"234_CR15","doi-asserted-by":"publisher","first-page":"972","DOI":"10.3389\/fphar.2020.00972","volume":"11","author":"P Spallarossa","year":"2020","unstructured":"Spallarossa P, Sarocchi M, Tini G, et al. How to monitor Cardiac complications of Immune checkpoint inhibitor therapy. Front Pharmacol. 2020;11:972. https:\/\/doi.org\/10.3389\/fphar.2020.00972","journal-title":"Front Pharmacol"},{"issue":"25","key":"234_CR16","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1200\/JCO.18.02464","volume":"37","author":"P Spallarossa","year":"2019","unstructured":"Spallarossa P, Tini G, Sarocchi M, et al. Identification and management of Immune Checkpoint inhibitor-related myocarditis: use troponin wisely. J Clin Oncol off J Am Soc Clin Oncol. 2019;37(25):2201\u20135. https:\/\/doi.org\/10.1200\/JCO.18.02464","journal-title":"J Clin Oncol off J Am Soc Clin Oncol"},{"issue":"10","key":"234_CR17","doi-asserted-by":"publisher","first-page":"3041","DOI":"10.1007\/s00262-021-02938-z","volume":"70","author":"A Inno","year":"2021","unstructured":"Inno A, Maurea N, Metro G, Carbone A, Russo A, Gori S. Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports. Cancer Immunol Immunother CII. 2021;70(10):3041\u201353. https:\/\/doi.org\/10.1007\/s00262-021-02938-z","journal-title":"Cancer Immunol Immunother CII"},{"issue":"6","key":"234_CR18","doi-asserted-by":"publisher","first-page":"467","DOI":"10.2217\/imt-2019-0003","volume":"11","author":"M Asai","year":"2019","unstructured":"Asai M, Kato Y, Kawai S, et al. Management of cardiac tamponade during nivolumab of lung cancer with intrapericardial bleomycin: case report. Immunotherapy. 2019;11(6):467\u201372. https:\/\/doi.org\/10.2217\/imt-2019-0003","journal-title":"Immunotherapy"},{"issue":"7","key":"234_CR19","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11912-021-01070-6","volume":"23","author":"RP Patel","year":"2021","unstructured":"Patel RP, Parikh R, Gunturu KS, et al. Cardiotoxicity of Immune Checkpoint inhibitors. Curr Oncol Rep. 2021;23(7):79. https:\/\/doi.org\/10.1007\/s11912-021-01070-6","journal-title":"Curr Oncol Rep"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-024-00234-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-024-00234-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T06:03:25Z","timestamp":1715925805000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-024-00234-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,17]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["234"],"URL":"https:\/\/doi.org\/10.1186\/s40959-024-00234-0","relation":{},"ISSN":["2057-3804"],"issn-type":[{"value":"2057-3804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,17]]},"assertion":[{"value":"6 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this a systematic review no prior institutional review board and the ethics committee approval was obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Allan Klein: research funding from Kiniksa Pharmaceuticals, Ltd; and have served on scientific advisory boards for Cardiol Therapeutics, Kiniksa Pharmaceuticals, Ltd., Swedish Orphan Biovitrum AB, and Pfizer, Inc. All author others have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}